Mereo BioPharma(US:MREO)2026-03-19 12:41Financial Performance - The net loss for the full year ended December 31, 2025, was $41.9 million, compared to $43.3 million in 2024, reflecting an operating loss of $40.1 million[9]. - Revenue for the year ended December 31, 2025, is reported at $500 million, compared to no revenue in 2024[21]. - Operating loss decreased to $40.1 million in 2025 from $47.4 million in 2024, indicating improved operational efficiency[21]. - Net loss for 2025 is $41.9 million, a slight improvement from a net loss of $43.3 million in 2024[21]. - Loss per share improved to $0.05 in 2025 from $0.06 in 2024, indicating a reduction in losses on a per-share basis[21]. - Total comprehensive loss for 2025 is $33.9 million, compared to $44.6 million in 2024, showing a reduction in overall losses[21]. - Other comprehensive income from foreign currency translation adjustments was $8.0 million in 2025, contrasting with a loss of $1.4 million in 2024[21]. - Interest income decreased to $2.2 million in 2025 from $3.0 million in 2024, indicating a decline in interest-earning assets[21]. - The company reported a benefit from research and development tax credit of $1.9 million in 2025, slightly up from $1.6 million in 2024[21]. Research and Development - Total research and development expenses decreased by $3.2 million from $20.9 million in 2024 to $17.8 million in 2025, primarily due to reductions in expenses for alvelestat and etigilimab[7]. - Research and development expenses decreased to $17.8 million in 2025 from $20.9 million in 2024, reflecting cost management efforts[21]. - Mereo anticipates a single Phase 3 trial enrolling approximately 220 patients for alvelestat, with a primary efficacy endpoint based on the St. George's Respiratory Questionnaire Total Score[5]. - Setrusumab demonstrated statistically significant improvements in bone mineral density and reductions in vertebral fractures in pediatric patients, although it did not achieve statistical significance against primary endpoints[5]. - Mereo has designed a potential Phase 2b study of alvelestat in bronchiectasis to support ongoing partnering discussions[5]. Corporate Developments - Mereo is in active discussions for the Phase 3 development and commercialization of alvelestat, with potential partners indicating progress[5]. - The company has retained EU and UK commercial rights for setrusumab while partnering with Ultragenyx, which includes potential milestone payments of up to $245 million[12]. - The total ordinary shares issued as of December 31, 2025, were 795,658,504, an increase from 775,728,034 in 2024[11]. - Weighted average shares outstanding increased to 797.1 million in 2025 from 739.6 million in 2024, suggesting potential dilution effects[21]. Expenses - General and administrative expenses decreased by $3.4 million from $26.4 million in 2024 to $23.0 million in 2025, attributed to lower accruals for bonuses and reduced professional fees[8].